Cart
sales@molnova.com
Z-Lys-OH
CAS No. 2212-75-1
Z-Lys-OH( —— )
Catalog No. M35882 CAS No. 2212-75-1
Z-Lys-OH is a competitive inhibitor of papain, a lysine derivative.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | 27 | In Stock |
|
Biological Information
-
Product NameZ-Lys-OH
-
NoteResearch use only, not for human use.
-
Brief DescriptionZ-Lys-OH is a competitive inhibitor of papain, a lysine derivative.
-
DescriptionZ-Lys-OH is a lysine derivative.
-
In VitroAmino acids and amino acid derivatives have been commercially used as ergogenic supplements. They influence the secretion of anabolic hormones, supply of fuel during exercise, mental performance during stress related tasks and prevent exercise induced muscle damage. They are recognized to be beneficial as ergogenic dietary substances.
-
In Vivo——
-
Synonyms——
-
PathwayProteasome/Ubiquitin
-
TargetCysteine Protease
-
RecptorCysteine Protease
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2212-75-1
-
Formula Weight280.32
-
Molecular FormulaC14H20N2O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@H](NC(OCC1=CC=CC=C1)=O)(CCCCN)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.?
molnova catalog
related products
-
K777
K777 is an orally active and irreversible cysteine protease inhibitor. K777 is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry.
-
6'''-Feruloylspinosi...
6'''-Feruloylspinosin may possess anti-inflammatory activity.
-
(1S,2R)-Alicapistat
(1S,2R)-Alicapistat ((1S,2R)-ABT-957) is a highly efficient, orally active compound that selectively inhibits human calpains 1 and 2, showing promise for Alzheimer's disease (AD) therapy .
